¿Emergencia médica?¿Emergencia? Llame al 911. Salas de emergencias más cercanasEmergencias cercanas

Empresa farmacéutica (etiquetadora ante la FDA)

Accord Healthcare Inc.

Código de etiquetadora NDC: 16729

¿Qué es una etiquetadora?

La empresa cuyo nombre aparece en el envase y en el directorio de códigos nacionales de medicamentos (NDC) de la FDA. Puede fabricar el medicamento o vender uno fabricado por otra empresa. La primera parte de cada código NDC identifica a la etiquetadora.

Solo datos oficiales de la FDA

Los productos, aprobaciones y retiros vienen de la FDA (directorio NDC, Drugs@FDA, informes de retiros). Los retiros se vinculan a esta empresa por el código NDC del producto retirado.

Si tiene preguntas sobre su medicamento, hable con su médico o farmacéutico. En una emergencia, llame al 911.

De un vistazo

226Productos (NDC)

Medicamentos con receta

Mostrar los otros 44 medicamentos

Solicitudes de la FDA de estos productos

  • NDA: Solicitud de nuevo medicamento (NDA): así se aprueba un medicamento nuevo, normalmente de marca.
  • ANDA: Solicitud abreviada (ANDA): así se aprueba una versión genérica.
AprobadaSolicitudMedicamentoPatrocinador
28 de julio de 2026ANDA214306 Sugammadex
SUGAMMADEX SODIUM
Zenara
14 de noviembre de 2025ANDA218872 Lenalidomide
LENALIDOMIDE
Accord Hlthcare
3 de octubre de 2025ANDA219406 Clomiphene citrate
CLOMIPHENE CITRATE
Accord Hlthcare
23 de junio de 2025ANDA217845 Alcohol
DEHYDRATED ALCOHOL
Accord Hlthcare
7 de diciembre de 2022ANDA205574 Bendamustine hydrochloride
BENDAMUSTINE HYDROCHLORIDE
Accord Hlthcare
25 de mayo de 2022ANDA203485 Pemetrexed
PEMETREXED DISODIUM
Accord Hlthcare
11 de abril de 2022ANDA213236 Regadenoson
REGADENOSON
Accord Hlthcare
25 de enero de 2022ANDA212730 Pirfenidone
PIRFENIDONE
Accord Hlthcare
7 de octubre de 2021ANDA214845 Fluorouracil
FLUOROURACIL
Accord Hlthcare
26 de julio de 2021ANDA212868 Atropine
ATROPINE SULFATE
Accord Hlthcare
7 de junio de 2021NDA212035 Argatroban
ARGATROBAN IN SODIUM CHLORIDE
Accord Hlthcare
27 de abril de 2021ANDA208209 Vilazodone hydrochloride
VILAZODONE HYDROCHLORIDE
Accord Hlthcare
19 de marzo de 2021ANDA213424 Atropine
ATROPINE SULFATE
Accord Hlthcare
17 de noviembre de 2020ANDA211689 Fulvestrant
FULVESTRANT
Accord Hlthcare
28 de octubre de 2020ANDA207991 Fingolimod
FINGOLIMOD HYDROCHLORIDE
Accord Hlthcare
28 de octubre de 2020ANDA213936 Methylphenidate
METHYLPHENIDATE HYDROCHLORIDE
Accord Hlthcare
19 de octubre de 2020ANDA212399 Levothyroxine
LEVOTHYROXINE SODIUM
Accord Hlthcare
29 de septiembre de 2020NDA214652 Atropine
ATROPINE SULFATE
Accord Hlthcare
24 de septiembre de 2020ANDA210499 Dimethyl fumarate
DIMETHYL FUMARATE
Accord Hlthcare
17 de julio de 2020ANDA209069 Buprenorphine and naloxone
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
Wes Pharma Inc
8 de julio de 2020ANDA213238 Glycopyrrolate
GLYCOPYRROLATE
Accord Hlthcare
19 de junio de 2020ANDA213338 Dofetilide
DOFETILIDE
Accord Hlthcare
15 de mayo de 2020ANDA211892 Cinacalcet
CINACALCET HYDROCHLORIDE
Accord Hlthcare
28 de abril de 2020ANDA206997 Diltiazem
DILTIAZEM HYDROCHLORIDE
Accord Hlthcare
7 de abril de 2020ANDA213342 Hydroxychloroquine sulfate
HYDROXYCHLOROQUINE SULFATE
Accord Hlthcare
Mostrar las otras 71 solicitudes
AprobadaSolicitudMedicamentoPatrocinador
24 de enero de 2020ANDA213343 Methotrexate
METHOTREXATE SODIUM
Accord Hlthcare
12 de julio de 2019ANDA212667 Daptomycin
DAPTOMYCIN
Accord Hlthcare
24 de junio de 2019ANDA211961 Daptomycin
DAPTOMYCIN
Accord Hlthcare
26 de marzo de 2019ANDA209167 Tadalafil
TADALAFIL
Accord Hlthcare
22 de febrero de 2019ANDA210148 Busulfan
BUSULFAN
Accord Hlthcare Inc
7 de febrero de 2019ANDA209281 Olmesartan medoxomil and hydrochlorothiazide
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
Accord Hlthcare
31 de enero de 2019ANDA211688 Tacrolimus
TACROLIMUS
Accord Hlthcare
7 de enero de 2019ANDA209690 Teriflunomide
TERIFLUNOMIDE
Accord Hlthcare
3 de enero de 2019ANDA208049 Lurasidone hydrochloride
LURASIDONE HYDROCHLORIDE
Accord Hlthcare
31 de octubre de 2018ANDA210497 Bupropion
BUPROPION HYDROCHLORIDE
Accord Hlthcare
26 de octubre de 2018ANDA211550 Ezetimibe
EZETIMIBE
Accord Hlthcare
18 de octubre de 2018ANDA207659 Acetazolamide
ACETAZOLAMIDE
Accord Hlthcare
11 de julio de 2018ANDA206863 Dalfampridine
DALFAMPRIDINE
Accord Hlthcare
2 de julio de 2018ANDA207475 Azacitidine
AZACITIDINE
Accord Hlthcare
30 de marzo de 2018ANDA207687 Atorvastatin
ATORVASTATIN CALCIUM
Accord Hlthcare
2 de febrero de 2018ANDA205987 Prasugrel
PRASUGREL
Accord Hlthcare
29 de noviembre de 2017ANDA206252 Quetiapine
QUETIAPINE FUMARATE
Accord Hlthcare
22 de noviembre de 2017ANDA206551 Bivalirudin
BIVALIRUDIN
Accord Hlthcare
8 de septiembre de 2017ANDA206923 Trazodone hydrochloride
TRAZODONE HYDROCHLORIDE
Accord Hlthcare
23 de agosto de 2017ANDA202555 Mycophenolic acid
MYCOPHENOLATE SODIUM
Accord Hlthcare
13 de julio de 2017ANDA206922 Eplerenone
EPLERENONE
Accord Hlthcare
6 de julio de 2017ANDA204406 Topotecan
TOPOTECAN HYDROCHLORIDE
Accord Hlthcare
24 de abril de 2017ANDA207662 Olmesartan medoxomil
OLMESARTAN MEDOXOMIL
Accord Hlthcare
21 de marzo de 2017ANDA207474 Oxaliplatin
OXALIPLATIN
Accord Hlthcare
28 de febrero de 2017ANDA204022 Ropinirole
ROPINIROLE HYDROCHLORIDE
Accord Hlthcare
27 de febrero de 2017ANDA201528 Temozolomide
TEMOZOLOMIDE
Accord Hlthcare
27 de febrero de 2017ANDA203475 Decitabine
DECITABINE
Accord Hlthcare
9 de febrero de 2017ANDA206775 Carboplatin
CARBOPLATIN
Accord Hlthcare
7 de diciembre de 2016ANDA206251 Aripiprazole
ARIPIPRAZOLE
Accord Hlthcare
28 de noviembre de 2016ANDA205279 Zoledronic acid
ZOLEDRONIC ACID
Accord Hlthcare
17 de noviembre de 2016ANDA207068 Pravastatin sodium
PRAVASTATIN SODIUM
Accord Hlthcare
1 de noviembre de 2016ANDA090681 Quetiapine
QUETIAPINE FUMARATE
Accord Hlthcare
31 de octubre de 2016ANDA206434 Rosuvastatin
ROSUVASTATIN CALCIUM
Accord Hlthcare
19 de septiembre de 2016ANDA203512 Spironolactone
SPIRONOLACTONE
Accord Hlthcare
29 de febrero de 2016ANDA207138 Oxybutynin
OXYBUTYNIN CHLORIDE
Accord Hlthcare
9 de febrero de 2016ANDA204023 Dexmedetomidine
DEXMEDETOMIDINE HYDROCHLORIDE
Accord Hlthcare
4 de febrero de 2016NDA207174 Paricalcitol
PARICALCITOL
Accord Hlthcare
25 de noviembre de 2015ANDA202873 Clozapine
CLOZAPINE
Accord Hlthcare
18 de agosto de 2015ANDA206774 Cisplatin
CISPLATIN
Accord Hlthcare
13 de julio de 2015ANDA206846 Ondansetron
ONDANSETRON HYDROCHLORIDE
Accord Hlthcare
23 de abril de 2015ANDA202593 Capecitabine
CAPECITABINE
Accord Hlthcare
30 de diciembre de 2014ANDA202557 Buspirone
BUSPIRONE HYDROCHLORIDE
Accord Hlthcare
7 de noviembre de 2014ANDA202825 Sertraline hydrochloride
SERTRALINE HYDROCHLORIDE
Accord Hlthcare
11 de junio de 2014ANDA202824 Doxazosin
DOXAZOSIN MESYLATE
Accord Hlthcare
4 de junio de 2014ANDA202446 Amitriptyline hydrochloride
AMITRIPTYLINE HYDROCHLORIDE
Accord Hlthcare
5 de noviembre de 2013ANDA091643 Finasteride
FINASTERIDE
Accord Hlthcare
26 de junio de 2013ANDA202351 Topotecan
TOPOTECAN HYDROCHLORIDE
Accord Hlthcare
6 de mayo de 2013ANDA203154 Allopurinol
ALLOPURINOL
Accord Hlthcare
8 de febrero de 2013ANDA202323 Carbidopa and levodopa
CARBIDOPA AND LEVODOPA
Accord Hlthcare
24 de septiembre de 2012ANDA202556 Hydrochlorothiazide
HYDROCHLOROTHIAZIDE
Accord Hlthcare
21 de septiembre de 2012ANDA202717 Montelukast
MONTELUKAST SODIUM
Accord Hlthcare
11 de septiembre de 2012ANDA202389 Escitalopram
ESCITALOPRAM OXALATE
Accord Hlthcare
27 de marzo de 2012ANDA202152 Quetiapine
QUETIAPINE FUMARATE
Accord Hlthcare
31 de agosto de 2011ANDA091195 Tacrolimus
TACROLIMUS
Accord Hlthcare
17 de agosto de 2011ANDA091205 Naltrexone hydrochloride
NALTREXONE HYDROCHLORIDE
Accord Hlthcare
8 de junio de 2011NDA201195 Docetaxel
DOCETAXEL
Accord Hlthcare
3 de junio de 2011ANDA090934 Letrozole
LETROZOLE
Accord Hlthcare
28 de junio de 2010ANDA090568 Anastrozole
ANASTROZOLE
Accord Hlthcare
23 de febrero de 2010ANDA090121 Finasteride
FINASTERIDE
Accord Hlthcare
6 de julio de 2009ANDA078917 Bicalutamide
BICALUTAMIDE
Accord Hlthcare
4 de mayo de 2009ANDA065416 Mycophenolate mofetil
MYCOPHENOLATE MOFETIL
Accord Hlthcare
4 de mayo de 2009ANDA090253 Mycophenolate mofetil
MYCOPHENOLATE MOFETIL
Accord Hlthcare
26 de febrero de 2008ANDA078155 Simvastatin
SIMVASTATIN
Accord Hlthcare
23 de agosto de 2007ANDA078181 Glimepiride
GLIMEPIRIDE
Accord Hlthcare
30 de abril de 2007ANDA040716 Methotrexate
METHOTREXATE SODIUM PRESERVATIVE FREE
Accord Hlthcare
26 de abril de 2007ANDA040743 Fluorouracil
FLUOROURACIL
Accord Hlthcare
26 de abril de 2007ANDA040798 Fluorouracil
FLUOROURACIL
Accord Hlthcare
2 de mayo de 2005ANDA077147 Clonazepam
CLONAZEPAM
Accord Hlthcare
30 de abril de 1998ANDA064144 Mitomycin
MITOMYCIN
Accord Hlthcare
14 de marzo de 1996ANDA074513 Etoposide
ETOPOSIDE
Accord Hlthcare
15 de diciembre de 1986ANDA070017 Furosemide
FUROSEMIDE
Accord Hlthcare

El patrocinador es la empresa titular de la solicitud ante la FDA; puede ser distinta de la etiquetadora.

Cronología de retiros

2026

  1. 6 de agosto de 2026 · Clase II · En curso · D-0781-2026 · Levothyroxine

    Subpotent Drug

    Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), 1000-count bottles, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehrad

  2. 6 de agosto de 2026 · Clase II · En curso · D-0776-2026 · Levothyroxine

    Subpotent Drug

    Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 1000-count bottles, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun

  3. 6 de agosto de 2026 · Clase II · En curso · D-0775-2026 · Levothyroxine

    Subpotent Drug

    Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 1000-count bottles, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradu

  4. 6 de agosto de 2026 · Clase II · En curso · D-0782-2026 · Levothyroxine

    Subpotent Drug

    Levothyroxine Sodium Tablets, USP, 137 mcg (0.137 mg), packaged in a) 90-count bottles (NDC 16729-454-15) b) 1000-count bottles (NDC 16729-454-17), Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, M

  5. 6 de agosto de 2026 · Clase II · En curso · D-0783-2026 · Levothyroxine

    Subpotent Drug

    Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), 1000-count bottles, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradu

  6. 6 de agosto de 2026 · Clase II · En curso · D-0777-2026 · Levothyroxine

    Subpotent Drug

    Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 1000-count bottles, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradu

  7. 6 de agosto de 2026 · Clase II · En curso · D-0784-2026 · Levothyroxine

    Subpotent Drug

    Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), packaged in a) 90-count bottles (NDC 16729-456-15), and b) 1000-count bottles (NDC 16729-456-17), Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 276

  8. 6 de agosto de 2026 · Clase II · En curso · D-0780-2026 · Levothyroxine

    Subpotent Drug

    Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 1000-count bottles, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehrad

  9. 6 de agosto de 2026 · Clase II · En curso · D-0786-2026 · Levothyroxine

    Subpotent Drug

    Levothyroxine Sodium Tablets, USP, 300 mcg (0.3 mg), 90-count bottles, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-2

  10. 6 de agosto de 2026 · Clase II · En curso · D-0778-2026 · Levothyroxine

    Subpotent Drug

    Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 1000-count bottles, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradu

Mostrar los 50 retiros anteriores

2026

  1. 6 de agosto de 2026 · Clase II · En curso · D-0785-2026 · Levothyroxine

    Subpotent Drug

    Levothyroxine Sodium Tablets, USP, 200 mcg (0.2 mg), packaged in a) 90-count bottles (NDC 16729-457-15) and b) 1000-count bottles (NDC 16729-457-17), Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617,

  2. 6 de agosto de 2026 · Clase II · En curso · D-0779-2026 · Levothyroxine

    Subpotent Drug

    Levothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), packaged in a) 90-count bottles (NDC 16729-451-15) and b) 1000-count bottles, (NDC 16729-451-17), Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617

  3. 8 de junio de 2026 · Clase II · En curso · D-0656-2026 · Levothyroxine

    Subpotent Drug

    Levothyroxine Sodium Tablets, USP, 300 mcg (0.3mg), 90 Tablets bottles, Rx only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: lntas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-

2025

  1. 16 de septiembre de 2025 · Clase II · En curso · D-0006-2026 · Levothyroxine

    Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.

    Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 90 Tablets per bottle, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehra

  2. 20 de junio de 2025 · Clase II · En curso · D-0522-2025 · Levothyroxine

    Subpotent Drug: Assay below the approved specification

    Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradu

  3. 20 de junio de 2025 · Clase II · En curso · D-0523-2025 · Levothyroxine

    Subpotent Drug: Assay below the approved specification

    Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun

  4. 20 de junio de 2025 · Clase II · En curso · D-0518-2025 · Levothyroxine

    Subpotent Drug: Assay below the approved specification

    Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 90-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-2

  5. 20 de junio de 2025 · Clase II · En curso · D-0524-2025 · Levothyroxine

    Subpotent Drug: Assay below the approved specification

    Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradu

  6. 20 de junio de 2025 · Clase II · En curso · D-0521-2025 · Levothyroxine

    Subpotent Drug: Assay below the approved specification

    Levothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-

  7. 20 de junio de 2025 · Clase II · En curso · D-0520-2025 · Levothyroxine

    Subpotent Drug: Assay below the approved specification

    Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 90-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-24

  8. 20 de junio de 2025 · Clase II · En curso · D-0519-2025 · Levothyroxine

    Subpotent Drug: Assay below the approved specification

    Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun

  9. 10 de abril de 2025 · Clase II · En curso · D-0394-2025 · Levothyroxine

    Subpotent

    Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 1000 bottles, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 1

  10. 10 de abril de 2025 · Clase II · En curso · D-0396-2025 · Levothyroxine

    Subpotent

    Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 1000 bottles, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 1

  11. 10 de abril de 2025 · Clase II · En curso · D-0397-2025 · Levothyroxine

    Subpotent

    Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 90 bottles, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 19

  12. 10 de abril de 2025 · Clase II · En curso · D-0395-2025 · Levothyroxine

    Subpotent

    Levothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 1000 bottles, Rx Only, Manufactured for Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 19

2024

  1. 8 de noviembre de 2024 · Clase II · Cerrado por la FDA · D-0076-2025 · Levothyroxine

    Subpotent drug

    Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 1000-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-

  2. 10 de octubre de 2024 · Clase II · Cerrado por la FDA · D-0032-2025 · Cinacalcet

    CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

    Cinacalcet Tablets, 90 mg, Rx Only, a) 30 Tablets per bottle, NDC: 16729-442-10, b) 90 Tablets per bottle, NDC: 16729-442-15, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceut

  3. 10 de octubre de 2024 · Clase II · Cerrado por la FDA · D-0030-2025 · Cinacalcet

    CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

    Cinacalcet Tablets 30 mg, Rx Only, a) 30 Tablets per bottle, NDC: 16729-440-10, b) 90 Tablets per bottle, NDC: 16729-440-15, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703, Manufactured by: Intas Pharmaceuti

  4. 10 de octubre de 2024 · Clase II · Cerrado por la FDA · D-0031-2025 · Cinacalcet

    CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.

    Cinacalcet Tablets, 60 mg, Rx Only, a) 30 Tablets per bottle, NDC: 16729-441-10, b) 90 Tablets per bottle, NDC: 16729-441-15, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceut

  5. 1 de octubre de 2024 · Clase II · Cerrado por la FDA · D-0010-2025 · Cisplatin

    Failed Impurities/Degradation Specifications.

    Cisplatin Injection, 100mg/100mL (1mg/mL), For Intravenous Use, 100 mL Multiple Dose Vial, Rx Only, Manufactured for: Accord Healthcare Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahm

2023

  1. 3 de julio de 2023 · Clase II · Cerrado por la FDA · D-0918-2023 · Bivalirudin

    Presence of Particulate Matter: Particulate matter identified as fiber.

    Bivalirudin for Injection 250 mg, 10 Single-Dose Vials, Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited Ahmedabad-382 210, India, NDC 16729-275-67.

  2. 3 de julio de 2023 · Clase II · Cerrado por la FDA · D-0917-2023 · Atropine

    Presence of Particulate Matter: Particulate matter identified as fiber.

    Atropine Sulfate Injection, USP 8 mg per 20 mL (0.4 mg per mL), 20 mL Multiple Dose Vials, Rx only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited Ahmedabad-382

  3. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0400-2023 · Montelukast

    CGMP Deviations: recalling drug products following an FDA inspection.

    Montelukast Sodium Tablets, USP, 10 mg* Rx Only, Packaged as: a) 30-count bottle NDC 16729-119-10 UPC 3 16729 11910 8; b) 90-count bottle NDC 16729-119-15 UPC 3 16729 11915 3; c) 1,000-count bottle NDC 16729-119-17 UPC 3

  4. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0386-2023 · Doxazosin

    CGMP Deviations: recalling drug products following an FDA inspection.

    Doxazosin Tablets USP 1 mg, Rx Only, Packaged as: a) 100-count bottle NDC 16729-211-01 UPC 3 16729 21101 7; b) 1,000-count bottle NDC 16729-211-17 UPC 3 16729 21117 8; Manufactured for: Accord Healthcare, Inc., Durham, N

  5. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0387-2023 · Doxazosin

    CGMP Deviations: recalling drug products following an FDA inspection.

    Doxazosin Tablets USP, 2 mg, Rx Only, Packaged as: a) 100-count bottle NDC 16729-414-01 UPC 3 16729 41401 2; b) 1,000-count NDC 16729-414-17 UPC 3 16729 41417 3; Manufactured for: Accord Healthcare, Inc., Durham, NC 2770

  6. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0389-2023 · Doxazosin

    CGMP Deviations: recalling drug products following an FDA inspection.

    Doxazosin Tablets USP, 8 mg, Rx Only, Packaged in: a) 100 Tablets NDC 16729-415-01 UPC 3 16729 41501 9; b) 1,000 Tablets NDC 16729-415-17 UPC 3 16729 41517 0; Manufactured for: Accord Healthcare, Inc., Durham, NC 27703.

  7. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0430-2023 · Ropinirole

    CGMP Deviations: recalling drug products following an FDA inspection.

    rOPINIRole Tablets USP 4 mg* 100-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 INDIA, NDC 16729-237-01, UPC

  8. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0425-2023 · Ropinirole

    CGMP Deviations: recalling drug products following an FDA inspection.

    rOPINIRole Tablets USP 0.25 mg*, 100-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 INDIA. NDC 16729-232-01,

  9. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0431-2023 · Ropinirole

    CGMP Deviations: recalling drug products following an FDA inspection.

    rOPINIRole Tablets USP 5 mg* 100-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 INDIA, NDC 16729-238-01, UPC

  10. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0429-2023 · Ropinirole

    CGMP Deviations: recalling drug products following an FDA inspection.

    rOPINIRole Tablets USP 3 mg*, 100-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 INDIA, NDC 16729-236-01, UPC

  11. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0388-2023 · Doxazosin

    CGMP Deviations: recalling drug products following an FDA inspection.

    Doxazosin Tablets USP, 4 mg, Rx Only, Packaged as: a) 100-count bottle NDC 16729-213-01 UPC 3 16729 21301 1; b) 1,000-count bottle NDC 16729-213-17 UPC 3 16729 21317 2; Manufactured for: Accord Healthcare, Inc., Durham,

  12. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0428-2023 · Ropinirole

    CGMP Deviations: recalling drug products following an FDA inspection.

    rOPINIRole Tablets USP 2 mg*, 100-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 INDIA. NDC 16729-235-01, UPC

  13. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0427-2023 · Ropinirole

    CGMP Deviations: recalling drug products following an FDA inspection.

    rOPINIRole Tablets USP 1 mg*, 100-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 INDIA, NDC 16729-234-01, UPC

  14. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0390-2023 · Finasteride

    CGMP Deviations: recalling drug products following an FDA inspection.

    Finasteride Tablets USP, 1 mg, Rx Only, Packaged as: a) 30-count bottle NDC 16729-089-10 UPC 3 16729 08910 4; b) 90-count bottle NDC 16729-089-15 UPC 3 16729 08915 9; Manufactured for: Accord Healthcare, Inc., Durham, NC

  15. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0426-2023 · Ropinirole

    CGMP Deviations: recalling drug products following an FDA inspection.

    rOPINIRole Tablets USP 0.5 mg*, 100-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213 INDIA. NDC 16729-233-01, U

  16. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0371-2023 · Atorvastatin

    CGMP Deviations: recalling drug products following an FDA inspection.

    Atorvastatin Calcium Tablets USP, 10 mg* Rx Only, Packaged as a) 90 Tablets NDC 16729-044-15 UPC 3 16729 04415 8; b) 1,000 Tablets NDC 16729-044-17 UPC 3 16729 04417 2; Manufactured for: Accord Healthcare, Inc., Durham,

  17. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0424-2023 · Pravastatin sodium

    CGMP Deviations: recalling drug products following an FDA inspection.

    Pravastatin Sodium Tablets USP, 80 mg, Rx Only, 90- count bottle, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA, NDC 16729-0

  18. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0406-2023 · Rosuvastatin

    CGMP Deviations: recalling drug products following an FDA inspection.

    Rosuvastatin Tablets, USP 20 mg* Rx Only, Packaged as: a) 90-count bottle NDC 16729-286-15, UPC 3 16729 28615 2; b) 1,000-count bottles NDC 16729-286-17, UPC 3 16729 28617 6; Manufactured for: Accord Healthcare, Inc., Du

  19. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0375-2023 · Buspirone

    CGMP Deviations: recalling drug products following an FDA inspection.

    BusPIRone Hydrochloride Tablets USP 7.5 mg, 100-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA, NDC 16

  20. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0385-2023 · Dofetilide

    CGMP Deviations: recalling drug products following an FDA inspection.

    Dofetilide Capsules 500 mcg (0.5 mg), 60-count bottle, Rx only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA NDC 16729-492

  21. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0404-2023 · Rosuvastatin

    CGMP Deviations: recalling drug products following an FDA inspection.

    Rosuvastatin Tablets, USP, 5 mg*, Rx Only, Packaged as: a) 90-count bottle, NDC 16729-284-15, UPC 3 16729 28415 8; b) 1,000-count bottle, NDC 16729-284-17, UPC 3 16729 28417 2; Manufactured for: Accord Healthcare, Inc.,

  22. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0370-2023 · Aripiprazole

    CGMP Deviations: recalling drug products following an FDA inspection.

    Aripiprazole Tablets, USP 30 mg Rx Only, a) 30-count bottle, NDC 16729-283-10, UPC 3 16729 28310 6; b) 100-count bottle, NDC 16729-283-01, UPC 3 16729 28301 4; Manufactured for: Accord Healthcare, Inc., Durham, NC 27703.

  23. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0373-2023 · Atorvastatin

    CGMP Deviations: recalling drug products following an FDA inspection.

    Atorvastatin Calcium Tablets USP 40 mg* Rx Only, Packaged as a) 90 Tablets NDC 16729-046-15 UPC 3 16729 04615 2; b) 1,000 Tablets NDC 16729-046-17 UPC 3 16729 04617 6, Manufactured for: Accord Healthcare, Inc., Durham, N

  24. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0398-2023 · Glycopyrrolate

    CGMP Deviations: recalling drug products following an FDA inspection.

    Glycopyrrolate Injection, USP 1 mg/5 mL (0.2 mg/mL) 5 mL Multiple Dose Vial, x 10 vials carton, Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703, USA. Manufactured by: Intas Pharmaceuticals Limited, Ph

  25. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0378-2023 · Buspirone

    CGMP Deviations: recalling drug products following an FDA inspection.

    BusPIRone Hydrochloride Tablets USP, 10 mg 500-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA, NDC 167

  26. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0420-2023 · Pirfenidone

    CGMP Deviations: recalling drug products following an FDA inspection.

    Pirfenidone Tablets 801 mg, Rx Only, 90-count bottle, Manufactured for: Accord Healthcare, Inc., Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA. NDC 16729-468-15, UPC 3

  27. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0393-2023 · Glimepiride

    CGMP Deviations: recalling drug products following an FDA inspection.

    Glimepiride Tablets USP, 1 mg, Rx Only, Packaged in: a) 100-count bottle NDC 16729-001-01 UPC 3 16729 00101 4; b) 500-count bottle NDC 16729-001-16 UPC 3 16729 00116 8; Manufactured for: Accord Healthcare, Inc., Durham,

  28. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0382-2023 · Daptomycin

    CGMP Deviations: recalling drug products following an FDA inspection.

    Daptomycin for Injection 500 mg per vial, Single-dose vial, Rx only, Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213, INDIA. NDC 16729-435-05 UPC 3 16729 43505 5.

  29. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0412-2023 · Simvastatin

    CGMP Deviations: recalling drug products following an FDA inspection.

    Simvastatin Tablets USP 80 mg Rx Only, Packaged as: a) 90-count bottle NDC 16729-007-15, UPC 3 16729 00715 3; b) 1,000-count bottle NDC 16729-007-17, UPC 3 16729 00717 7; Manufactured for: Accord Healthcare, Inc., Durham

  30. 7 de febrero de 2023 · Clase II · Cerrado por la FDA · D-0394-2023 · Glimepiride

    CGMP Deviations: recalling drug products following an FDA inspection.

    Glimepiride Tablets USP, 2 mg, Rx Only, Packaged in: a) 100 Tablets NDC 16729-002-01 UPC 3 16729 00201 1; b) 500 Tablets NDC 16729-002-16 UPC 3 16729 00216 5; Manufactured for: Accord Healthcare, Inc., Durham, NC 27703.

Se muestran los 60 más recientes de 95.

¿Qué significan las clases de retiro?

Clase I: El tipo más grave: existe una probabilidad razonable de que usar el producto cause problemas de salud graves o la muerte.
Clase II: Usar el producto puede causar problemas de salud temporales o reversibles con tratamiento, o la probabilidad de problemas graves es remota.
Clase III: No es probable que usar el producto cause problemas de salud (por ejemplo, un problema de etiquetado o de envase).

Fuentes

  1. NDC Directory (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  2. Drugs@FDA (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  3. Drug recall enforcement reports (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 10 de noviembre de 2026, consultados el 14 de noviembre de 2026

Buscador de informes de retiros de la FDA → · Informar un error →